Core Viewpoint - Roche announced a commitment to invest USD 50 billion in the United States over the next five years, aimed at enhancing its manufacturing and R&D capabilities, which is expected to create over 12,000 new jobs [1][2][6]. Company Investment and Expansion - The investment will expand Roche's existing footprint of more than 25,000 employees across 24 sites in eight US states [2][6]. - New facilities will include state-of-the-art R&D sites and expanded manufacturing capabilities in Indiana, Pennsylvania, Massachusetts, and California, with an additional site to be announced [6][7]. Job Creation - The investment is projected to create more than 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities [1][6]. Manufacturing and R&D Focus - Roche will enhance its manufacturing and distribution capabilities for innovative medicines and diagnostics in states such as Kentucky, Indiana, New Jersey, Oregon, and California [7]. - A new gene therapy manufacturing facility will be established in Pennsylvania, along with a 900,000 square foot manufacturing center for next-generation weight loss medicines [7]. Commitment to Innovation - The investment is positioned as a foundation for Roche's next era of innovation and growth, benefiting patients in the US and globally [2][6]. - Roche's CEO emphasized the company's long-standing commitment to research, development, and manufacturing in the US, highlighting its 110-year legacy in the country [2].